2022 Emerging Science Abstracts
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
The Science Committee is committed to presenting the best neuroscientific research at the Annual Meeting and is pleased to share the following Emerging Science abstracts, which qualified by having key aspects of research conducted after the October 11, 2021, abstract submission deadline. They are new and of sufficient scientific importance to warrant expedited presentation and publication.
- Received May 18, 2022.
- Accepted in final form May 18, 2022.
- © 2022 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
- Article
- Efficacy and Safety of Trofinetide for the Treatment of Rett Syndrome: Results From the Pivotal Phase 3 LAVENDER Study
- Pivotal Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Intra-Erythrocyte Dexamethasone Sodium Phosphate (ATTeST) on the Neurologic Motor Function of People With Ataxia Telangiectasia
- Ecopipam in Children and Adolescents With Tourette Syndrome: Results From a Randomized, Double-Blind, Placebo-Controlled Phase 2b Study
- Efficacy and Safety of P2B001 in the Management of Early Parkinson Disease: Results From a Phase 3, Randomized, Double-Blind, Double-Dummy Controlled Trial
- Plasma-Based Biomarkers in Phase 2 Study of Donanemab in Early, Symptomatic Alzheimer Disease
- Long-term Safety of a Fully Implanted Endovascular Brain-Computer Interface for Severe Paralysis: Results of SWITCH, a First-in-Human Study
- SAGE-718 in Patients With Mild Cognitive Impairment or Mild Dementia due to Alzheimer Disease: Results From the Phase 2 LUMINARY Study
- Long-term Survival of Randomized Participants Enrolled in the Phase 2 RESCUE-ALS Trial of CNM-Au8: A Cellular Energetic Catalyst
- Comparative Safety and Efficacy of Different Corticosteroid Regimens for Duchenne Muscular Dystrophy: Results of an International Randomized Controlled Trial
- Cognitive Symptoms After Mild SARS-CoV-2 Infection Associate With Higher Levels of CSF Immune Activation and Immunovascular Markers
- Lecanemab: An Assessment of the Clinical Effects, the Correlation of the Plasma Aβ 42/40 Ratio With Changes in Brain Amyloid PET SUVr, and Safety From the Core and Open-Label Extension of the Phase 2 Proof-of-Concept Study, BAN2401-G000-201, in Subjects With Early Alzheimer Disease
- Effectiveness of COVID-19 Vaccines in Patients With Multiple Sclerosis Receiving Disease-Modifying Therapies in England
- KINECT-HD: Results From a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Valbenazine for Chorea Associated With Huntington Disease
- Info & Disclosures
Dr. Deborah Friedman and Dr. Stacy Smith
► Watch
Related Articles
- No related articles found.